Azadeh is an Australian qualified solicitor and joined EIP from one of the largest specialist IP firms in Australia. She has advised both innovator and generic multi-national pharmaceutical companies throughout all stages of contentious patent proceedings, with experience in small-molecules, biologics and biosimilars. She notably represented ICOS (Eli Lilly) in a high profile case in the Federal Court of Australia.
Azadeh has a BSc in Biomedical Science and a Juris Doctor from Murdoch University, and a Graduate Diploma of Legal Practice from the Australian College of Law.
Erfahrung
- Apotex Pty Ltd v ICOS Corporation (No 3) [2018] FCA 1204
- Apotex Pty Ltd v ICOS Corporation [2017] FCA 466
Veröffentlichungen
- January 2023
LSIPR, Why Novartis lost its treatment dispute with Teva (link) - January 2023
EIP Updates, Court of Appeal refuses Arrow declaratory relief for Teva in a stand against forum shopping and jurisdictional imperialism (link) - December 2022
EIP Updates, Novartis overloaded with reasons its iron overload treatment Exjade is obvious and not infringed by Teva (link) - August 2022
Company, Women in Law: A Legal Timeline, in celebration of Women’s Equality Day (link) - June 2022
Update, Patents Court affirms power to grant injunctions for pre-grant patents, but Novartis loses on interim relief and refused permission to appeal by Birss LJ for Gilenya® (link)
Ausbildung und Qualifikationen
-
2015 — 2016
Graduate Diploma of Legal Practice , College of Law (Australia) -
2011 — 2014
Juris Doctor, Murdoch University -
2007 — 2010
BSc Biomedical Science, Murdoch University
Beruflicher Werdegang
- 2020 — present
Associate, EIP - 2016 — 2019
Lawyer, Wrays - 2014 — 2016
Analyst, Deloitte
Sprachen
- Farsi (fluent)